189 related articles for article (PubMed ID: 21812534)
1. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge.
Montes-Moreno S; Montalbán C; Piris MA
Leuk Lymphoma; 2012 Feb; 53(2):185-94. PubMed ID: 21812534
[TBL] [Abstract][Full Text] [Related]
2. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.
Colomo L; Loong F; Rives S; Pittaluga S; Martínez A; López-Guillermo A; Ojanguren J; Romagosa V; Jaffe ES; Campo E
Am J Surg Pathol; 2004 Jun; 28(6):736-47. PubMed ID: 15166665
[TBL] [Abstract][Full Text] [Related]
3. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.
Montes-Moreno S; Gonzalez-Medina AR; Rodriguez-Pinilla SM; Maestre L; Sanchez-Verde L; Roncador G; Mollejo M; García JF; Menarguez J; Montalbán C; Ruiz-Marcellan MC; Conde E; Piris MA
Haematologica; 2010 Aug; 95(8):1342-9. PubMed ID: 20418245
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphomas with plasmablastic differentiation.
Teruya-Feldstein J
Curr Oncol Rep; 2005 Sep; 7(5):357-63. PubMed ID: 16091196
[TBL] [Abstract][Full Text] [Related]
5. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.
Valera A; Colomo L; Martínez A; de Jong D; Balagué O; Matheu G; Martínez M; Taddesse-Heath L; Jaffe ES; Bacchi CE; Campo E
Mod Pathol; 2013 Oct; 26(10):1329-37. PubMed ID: 23599149
[TBL] [Abstract][Full Text] [Related]
6. Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation.
Hu M; Trevino J; Yang L; Cao D; Liu X; Lai J
In Vivo; 2018; 32(2):413-417. PubMed ID: 29475930
[TBL] [Abstract][Full Text] [Related]
7. CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.
Li J; Zhao S; Wang J; Chen J; Wen W; Zhang Q
Tumour Biol; 2016 Mar; 37(3):3619-37. PubMed ID: 26459310
[TBL] [Abstract][Full Text] [Related]
8. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.
Castillo JJ; Chavez JC; Hernandez-Ilizaliturri FJ; Montes-Moreno S
Expert Rev Hematol; 2015 Jun; 8(3):343-54. PubMed ID: 25641215
[TBL] [Abstract][Full Text] [Related]
9. De Novo Unclassifiable CD20-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge.
AbdullGaffar B; Seliem RM
Int J Surg Pathol; 2018 May; 26(3):266-270. PubMed ID: 28982264
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features.
Balagué O; Martínez A; Colomo L; Roselló E; Garcia A; Martínez-Bernal M; Palacín A; Fu K; Weisenburger D; Colomer D; Burke JS; Warnke RA; Campo E
Am J Surg Pathol; 2007 Sep; 31(9):1310-22. PubMed ID: 17721185
[TBL] [Abstract][Full Text] [Related]
11. FLI-1 is expressed in a wide variety of hematolymphoid neoplasms: a special concern in the differential diagnosis.
Cho U; Cha HJ; Kim HJ; Min SK; Kim HK; Jung HR; Park G; Kim JE
Clin Exp Med; 2024 Jan; 24(1):18. PubMed ID: 38280044
[TBL] [Abstract][Full Text] [Related]
12. Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches.
Chen BJ; Chuang SS
Adv Anat Pathol; 2020 Mar; 27(2):61-74. PubMed ID: 31725418
[TBL] [Abstract][Full Text] [Related]
13. Plasmablastic lymphoma and related disorders.
Hsi ED; Lorsbach RB; Fend F; Dogan A
Am J Clin Pathol; 2011 Aug; 136(2):183-94. PubMed ID: 21757592
[TBL] [Abstract][Full Text] [Related]
14. CD31 expression in plasmacytic/plasmablastic lesions.
Plocharczyk E; Wakely PE
Ann Diagn Pathol; 2013 Dec; 17(6):498-501. PubMed ID: 24074836
[TBL] [Abstract][Full Text] [Related]
15. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.
Garcia JF; Roncador G; García JF; Sánz AI; Maestre L; Lucas E; Montes-Moreno S; Fernandez Victoria R; Martinez-Torrecuadrara JL; Marafioti T; Mason DY; Piris MA
Haematologica; 2006 Apr; 91(4):467-74. PubMed ID: 16585013
[TBL] [Abstract][Full Text] [Related]
16. CD117 expression in diffuse large B-cell lymphomas: fact or fiction?
Vakiani E; Cattoretti G; Colovai AI; Murty VV; Alobeid B; Bhagat G
Pathol Int; 2005 Nov; 55(11):716-23. PubMed ID: 16271084
[TBL] [Abstract][Full Text] [Related]
17. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
Simonitsch-Klupp I; Hauser I; Ott G; Drach J; Ackermann J; Kaufmann J; Weltermann A; Greinix HT; Skrabs C; Dittrich C; Lutz D; Pötter R; Mannhalter C; Lechner K; Chott A; Jaeger U
Leukemia; 2004 Jan; 18(1):146-55. PubMed ID: 14603341
[TBL] [Abstract][Full Text] [Related]
18. Plasmablastic lymphoma: current perspectives.
Lopez A; Abrisqueta P
Blood Lymphat Cancer; 2018; 8():63-70. PubMed ID: 31360094
[TBL] [Abstract][Full Text] [Related]
19. Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
Morley AM; Verity DH; Meligonis G; Rose GE
Orbit; 2009; 28(6):425-9. PubMed ID: 19929677
[TBL] [Abstract][Full Text] [Related]
20. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Guedez L; Martinez A; Zhao S; Vivero A; Pittaluga S; Stetler-Stevenson M; Raffeld M; Stetler-Stevenson WG
Blood; 2005 Feb; 105(4):1660-8. PubMed ID: 15479729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
